Rhabdomyosarcoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Funding
• Clinical Trials

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Conditions:   Ependymoma;   Ewing Sarcoma;   High-grade Glioma;   Leukemia and Lymphoma;   Medulloblastoma;   Miscellaneous Brain Tumors;   Miscellaneous Solid Tumors;   Neuroblastoma;   Relapsed, Refractory Malignant Neoplasms;   Rhabdomyosarcoma Interventions:   Biological: Nivolumab;   Biological: NKTR-214 Sponsors:   Bristol-Myers Squibb;   Nektar Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2021 Category: Research Source Type: clinical trials